Cargando…

Enhanced Absorption of Insulin Aspart as the Result of a Dispersed Injection Strategy Tested in a Randomized Trial in Type 1 Diabetic Patients

OBJECTIVE: We investigated the impact of two different injection strategies on the pharmacokinetics and pharmacodynamics of insulin aspart in vivo in an open-label, two-period crossover study and verified changes in the surface-to-volume ratio ex vivo. RESEARCH DESIGN AND METHODS: Before the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mader, Julia K., Birngruber, Thomas, Korsatko, Stefan, Deller, Sigrid, Köhler, Gerd, Boysen, Susanne, Augustin, Thomas, Mautner, Selma I., Sinner, Frank, Pieber, Thomas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609526/ https://www.ncbi.nlm.nih.gov/pubmed/23193211 http://dx.doi.org/10.2337/dc12-1319

Ejemplares similares

Dermal open flow microperfusion for PK-based clinical bioequivalence studies of topical drug products
por: Birngruber, Thomas, et al.
Publicado: (2022)

Glucose Levels at the Site of Subcutaneous Insulin Administration and Their Relationship to Plasma Levels
por: Lindpointner, Stefan, et al.
Publicado: (2010)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study
por: Koehler, Gerd, et al.
Publicado: (2013)

Use of the Site of Subcutaneous Insulin Administration for the Measurement of Glucose in Patients With Type 1 Diabetes
por: Lindpointner, Stefan, et al.
Publicado: (2010)

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus
por: Korsatko, S., et al.
Publicado: (2013)

Long-Term Implanted cOFM Probe Causes Minimal Tissue Reaction in the Brain
por: Birngruber, Thomas, et al.
Publicado: (2014)

Assessment of Blood-Brain Barrier Function and the Neuroinflammatory Response in the Rat Brain by Using Cerebral Open Flow Microperfusion (cOFM)
por: Ghosh, Arijit, et al.
Publicado: (2014)

Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence
por: Bodenlenz, Manfred, et al.
Publicado: (2016)

Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart
por: Pieber, Thomas R., et al.
Publicado: (2019)

Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast‐acting insulin aspart compared with insulin aspart
por: Basu, Ananda, et al.
Publicado: (2018)

Subcutaneous glucose monitoring in patients with severe sepsis
por: Mader, JK, et al.
Publicado: (2007)

Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
por: Kildegaard, Jonas, et al.
Publicado: (2019)

A prolonged run-in period of standard subcutaneous microdialysis ameliorates quality of interstitial glucose signal in patients after major cardiac surgery
por: Moser, Othmar, et al.
Publicado: (2018)

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes
por: Heise, Tim, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes
por: Svehlikova, Eva, et al.
Publicado: (2021)

Variability of Skin Pharmacokinetic Data: Insights from a Topical Bioequivalence Study Using Dermal Open Flow Microperfusion
por: Bodenlenz, Manfred, et al.
Publicado: (2020)

An Untargeted Metabolomics Approach to Characterize Short-Term and Long-Term Metabolic Changes after Bariatric Surgery
por: Narath, Sophie H., et al.
Publicado: (2016)

The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes
por: Brunner, Martina, et al.
Publicado: (2015)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Dubai cohort of the A(1)chieve study
por: Gulzar, Zain, et al.
Publicado: (2013)

The Absorption of Needle-Free Insulin Aspart Through Jet Injector in Different Body Parts of Healthy Individuals
por: Pan, Qi, et al.
Publicado: (2022)

Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials
por: Rose, Ludger, et al.
Publicado: (2019)

The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes
por: Biester, Torben, et al.
Publicado: (2020)

Digital algorithm-guided insulin therapy in home healthcare for elderly persons with type 2 diabetes: A proof-of-concept study
por: Kopanz, Julia, et al.
Publicado: (2022)

Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine
por: Hauzenberger, Jasmin R., et al.
Publicado: (2017)

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
por: Hövelmann, Ulrike, et al.
Publicado: (2017)

Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice
por: Evans, Mark, et al.
Publicado: (2019)

The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes
por: Haluzík, Martin, et al.
Publicado: (2018)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study
por: Ozer, Kerem, et al.
Publicado: (2021)

Absorption and dispersion of ultrasonic waves
por: Herzfeld, Karl F, et al.
Publicado: (1959)

Survival assessment of the extended‐wear insulin infusion set featuring lantern technology in adults with type 1 diabetes by the glucose clamp technique
por: Simic, Amra, et al.
Publicado: (2021)

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
por: Mader, Julia K., et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes
por: Svehlikova, Eva, et al.
Publicado: (2023)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
por: Bowering, K., et al.
Publicado: (2018)

Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system
por: Kaineder, K, et al.
Publicado: (2017)

Study protocol for assessing the user acceptance, safety and efficacy of a tablet-based workflow and decision support system with incorporated basal insulin algorithm for glycaemic management in participants with type 2 diabetes receiving home health care: A single-centre, open-label, uncontrolled proof-of-concept study
por: Libiseller, Angela, et al.
Publicado: (2020)

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
por: Heise, T., et al.
Publicado: (2015)

Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin
por: Matheu, Victor, et al.
Publicado: (2005)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uurnd4brsjnsts8v93qa7kvbco